CD274 and non-small cell lung carcinoma: In contrast, for patients with stage IV squamous NSCLC with high PD-L1 and PS of 0–1, single-agent pembrolizumab, atezolizumab, or cemiplimab is recommended, whereas other options have not received strong recommendations.